The trial is an open-label assessment of the interaction of imeglimin with cimetidine. Up to
16 healthy men and women will receive a single oral dose of 1,500 mg imeglimin alone followed
by a second dose of imeglimin during repeated doses of 400 mg cimetidine taken twice daily
for 6 days.